Telix Pharma to buy ITM Isotope for $1.65 billion
Australia's Telix Pharmaceuticals has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. ITM shareholders are expected to receive about $1.25 billion in Telix shares at $11.84 per share.
On Sept 21, Australia’s Telix Pharmaceuticals said it has agreed to buy Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. After adjustments, ITM shareholders are expected to receive about $1.25 billion in Telix shares priced at $11.84 each.